Accelerate Diagnostics (NASDAQ:AXDX) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) in a report released on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Several other research firms have also commented on AXDX. Craig Hallum reduced their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating for the company in a research report on Monday. William Blair reaffirmed an “outperform” rating on shares of Accelerate Diagnostics in a research report on Tuesday.

View Our Latest Research Report on AXDX

Accelerate Diagnostics Stock Performance

AXDX opened at $0.91 on Thursday. The stock has a market capitalization of $13.19 million, a P/E ratio of -0.19 and a beta of 0.52. The company’s 50-day simple moving average is $1.09 and its two-hundred day simple moving average is $3.54. Accelerate Diagnostics has a 52-week low of $0.83 and a 52-week high of $11.90.

Institutional Investors Weigh In On Accelerate Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Griffin Asset Management Inc. increased its holdings in Accelerate Diagnostics by 3.0% in the 4th quarter. Griffin Asset Management Inc. now owns 1,219,724 shares of the medical research company’s stock worth $4,781,000 after acquiring an additional 35,146 shares in the last quarter. Tejara Capital Ltd purchased a new stake in Accelerate Diagnostics in the 3rd quarter worth approximately $78,000. Sonora Investment Management Group LLC purchased a new stake in Accelerate Diagnostics in the 3rd quarter worth approximately $63,000. TCI Wealth Advisors Inc. purchased a new stake in Accelerate Diagnostics in the 3rd quarter worth approximately $337,000. Finally, Geode Capital Management LLC increased its holdings in Accelerate Diagnostics by 31.8% in the 2nd quarter. Geode Capital Management LLC now owns 655,906 shares of the medical research company’s stock worth $531,000 after acquiring an additional 158,383 shares in the last quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Articles

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.